GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (FRA:R2WA) » Definitions » Other Operating Expense

Beximco Pharmaceuticals (FRA:R2WA) Other Operating Expense : €40.2 Mil (TTM As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Beximco Pharmaceuticals Other Operating Expense?

Beximco Pharmaceuticals's Other Operating Expense for the three months ended in Dec. 2024 was €0.9 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was €40.2 Mil.

Beximco Pharmaceuticals's quarterly Other Operating Expense declined from Jun. 2024 (€37.8 Mil) to Sep. 2024 (€0.8 Mil) but then increased from Sep. 2024 (€0.8 Mil) to Dec. 2024 (€0.9 Mil).

Beximco Pharmaceuticals's annual Other Operating Expense increased from Jun. 2022 (€32.8 Mil) to Jun. 2023 (€35.8 Mil) and increased from Jun. 2023 (€35.8 Mil) to Jun. 2024 (€39.9 Mil).


Beximco Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Beximco Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Other Operating Expense Chart

Beximco Pharmaceuticals Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.15 24.85 32.82 35.77 39.91

Beximco Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.64 37.83 0.81 0.91

Beximco Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €40.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beximco Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Beximco Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.

Beximco Pharmaceuticals Headlines

No Headlines